Review Article

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review

Table 4

Previous therapy history of biological DMARDs.

PatientGenderAgeOcular inflammationADAIFXETNRTXGOLCERABATCZ

1Female59KeratitisNANANANANANA+NA
2Female45Anterior and intermediate uveitis++NANANA+NANA
3Female40ScleritisNANANANANANANANA
4Female22Anterior uveitis++NA++NANA+
5Female45Scleritis+NA++NANANA+
6Female43Panuveitis++NA+NANA++
7Female18Panuveitis++NA+NANA+NA
8Female37Anterior uveitis++NANA+NANA+
9Male21Panuveitis++++NANA++
10Male65ScleritisNANANANANANANANA
11Male43Conjunctivitis+NANA+NANANANA

Notes: ADA: adalimumab; IFX: infliximab; ETN: etanercept; RTX: rituximab; GOL: golimumab; CER, certolizumab pegol; ABA: abatacept; TCZ: tocilizumab; NA: not available.